BioSpace News Archive

Alcami Corporation, a leading contract development and manufacturing organization, announced the appointment of Jamie Iudica to Chief Manufacturing Officer.

Molecular Templates, Inc. has received clearance by the United States Food and Drug Administration (“FDA”) following review of its Investigational New Drug Application (“IND”) to proceed for clinical testing of its novel MT-8421 ETB program targeting CTLA-4 in patients with relapsed/refractory solid tumors previously exposed to checkpoint inhibitors.

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”), a leader in pharmaceutical films, will be participating in the 35th Annual ROTH Conference, being held March 12–14, 2023 at the Ritz-Carlton Hotel in Dana Point, California.

Prolira BV has appointed Dominic J. Spadafore as its new Chief Executive Offer (CEO).

LivaNova PLC, a market-leading medical technology and innovation company, announced Damien McDonald, Chief Executive Officer, will present in a fireside chat at the Barclays Global Healthcare Conference in Miami, Florida.

At this year’s American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting, held March 7 to 11 in Las Vegas, Hospital for Special Surgery (HSS) presented new research on a variety of topics in orthopedic surgery, including studies related to minimally invasive surgery, racial disparities, and opioid alternatives for pain management in spine care.

Stuart Therapeutics, Inc. today announced that it is sponsoring two research poster presentations by researchers at Vanderbilt University and the University of Rochester at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, which will take place from April 23-27, 2023, in New Orleans, Louisiana.

Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today reported financial results for the fourth quarter and full-year ended December 31, 2022, and provided a strategic update.

Codexis, Inc., a leading enzyme engineering company, announced the approval of equity grants to two new employees as approved by the Compensation Committee of Codexis’s Board of Directors.